Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies (SHIMMER)

Dementia with Lewy bodies (DLB) is a progressive disorder affecting thinking, movement, behavior and sleep. Because currently there are no FDA-approved treatments for DLB, developing safe and effective treatments is the #1 priority for DLB research.

What is this study about?

The purpose of this clinical trial is to learn about the safety of CT1812 and how well it is tolerated. The study will also test how well CT1812 will treat mild to moderate DLB.

What’s involved?

Study participants will attend 12 study visits over 8 months. During that time, participants will be randomly assigned to take the study drug or a placebo (a pill with no active ingredients) for six months.

Who can participate?

You may be able to participate if you are:

  • Between the ages of 50 to 85
  • Have been diagnosed with mild to moderate dementia with Lewy bodies (DLB)
  • Have a caregiver/study partner who is willing and able to attend all study visits and participate in some study assessments

Study Sites:

State City Study Site Name Study Coordinator Email and Phone Number
Arizona Phoenix Barrow Neurological Institute Jalisa Santiago 800-392-2222
Arizona Sun City Banner Sun Health Research Institute Michele Gutierrez BSHRI.info@bannerhealth.com
623-832-6573
Arizona Tucson University of Arizona – Health Sciences Center Scott Silviu Richards scottrichards@arizona.edu
520-626-3576
California Fountain Valley The Parkinson’s and Movement Disorder Institute Evan Moreno-Davis evan@pmdi.org
714-378-5021
California Palo Alto Stanford University Stephanie Tran trans@stanford.edu
650-521-7287
California Santa Monica Pacific Neuroscience Institute Marisol Savage PNIFClinicalTrials@pacificneuro.org
Colorado Aurora University of Colorado Franklin Roberts, BS
Lauren McCall
neuroresearch@cuanschutz.edu
303-724-4644
lauren.mccall@cuanschutz.edu
303-724-3624
Colorado Englewood Cenexel RMCR Beth Capozzi b.capozzi@cenexel.com
303-867-5468
Florida Boca Raton University of Miami Adolfo M. Henriquez amh122@med.miami.edu
561-869-6820
Florida Boca Raton Parkinson’s Disease and Movement Disorders Center of Boca Raton info@parkinsonscenter.org
561-392-1818 ext 2
Florida Lady Lake Charter Research Omar Cortes omar.cortes@charterresearch.com
essie.luttrell@charterresearch.com
352-775-1000
Florida Ocala Renstar Medical Research Alyssa Ashley alyssa.ashley@renstar.net
352-629-5800
Kansas Fairway The University of Kansas Alzheimer’s Disease Research Center Alexandria Montero amontero@kumc.edu
Main Center: 913-588-0555
Ally direct: 913-574-2512
Kentucky Lexington University of Kentucky – Sanders Brown Center on Aging Keisha Jones kcl.jones@uky.edu
859-323-1331
Minnesota Rochester Mayo Clinic Elizabeth Abrahamson abrahamson.elizabeth@mayo.edu
New York New York Columbia University Katrina Cuasay kc2305@cumc.columbia.edu
212-305-2077
Oregon Portland Oregon Health and Science University Morgan Wilhelmi wilhelmo@ohsu.edu
503-494-7235
Washington Kirkland EvergreenHealth Research evergreenresearch@evergreenhealthcare.org
425-899-5385
Washington Seattle University of Washington Aasiya Islam aislam1@uw.edu
206-744-1822

Study Sponsor:

Cognition Therapeutics

This study was funded by the National Institute on Aging, National Institutes of Health